Homozygous or compound heterozygous alterations in AMH associated with loss of function (type 1) or AMHR2 determining receptor resistance (type 2) [73] have been identified in approximately 88% of PMDS cases [60,74]. This evidence concerns the gene AMHR2 and persistent Mullerian duct syndrome.